MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 04.04.2026
Novo Nordisk A/S Langfristiger Schuldenstrom 2011-2026 | NVO
Langfristiger Schuldenstrom Jährlich Novo Nordisk A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.34 B | 1.34 B | 1.17 B | 986 M | 822 M | 775 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in DKK-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.34 B | 775 M | 1.07 B |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.85 | 3.22 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 327.75 | -1.69 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Aligos Therapeutics
ALGS
|
3.58 M | $ 7.65 | 3.1 % | $ 75.6 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.44 | 1.03 % | $ 346 M | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.62 | -0.28 % | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 99.29 | -0.18 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.1 | -4.32 % | $ 5.1 M | Israel |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
671 K | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.41 | -9.03 % | $ 363 M | USA |
 |
Galectin Therapeutics
GALT
|
22 K | $ 2.36 | -7.81 % | $ 151 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.18 | -1.5 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.23 | -1.42 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.68 | -0.12 % | $ 6.83 B |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.48 | -0.67 % | $ 394 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
364 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 33.44 | -1.27 % | $ 2.22 B | USA |
 |
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | USA |